Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed has initiated a phase II study to evaluate its investigational compound MKC-1 in advanced metastatic breast cancer patients.
Subscribe to our email newsletter
The study will be conducted at approximately 15 centers in the US, and is expected to enroll patients with advanced or metastatic breast cancer who have failed conventional therapies.
EntreMed received the rights to MKC-1 after agreeing to acquire Miikana Therapeutics in December 2005. Miikana itself licensed the drug from Roche in May of last year.
The drug has demonstrated broad-acting anti-tumor effects in multiple animal models, including paclitaxel-resistant models. MKC-1 was evaluated in several phase I and II clinical studies prior to its acquision by Miikana. These studies resulted in extensive pharmacokinetic and safety data.
“We are pleased to hit the ground running with the Miikana team. The addition of MKC-1 to EntreMed’s clinical pipeline is consistent with our expertise in cell cycle regulation and our continuing emphasis on anticancer agents with novel mechanisms of action,” commented Carolyn Sidor, EntreMed’s chief medical officer.